top of page
Search

The Future of Biopharma Will Be Built Through East–West Collaboration

  • 21 hours ago
  • 8 min read

The global life sciences industry is entering a new era — one defined not by isolated innovation ecosystems, but by increasingly interconnected partnerships between East and West.


For decades, the biopharma industry largely followed a predictable model: scientific innovation and commercialisation were concentrated in Western markets, while Asia primarily served as a manufacturing and outsourcing destination. That dynamic is rapidly changing.


Today, Eastern biotech ecosystems — particularly across China, South Korea, Singapore, and the broader Asia-Pacific region — are becoming major contributors to scientific innovation, advanced manufacturing, and next-generation therapeutic development. At the same time, Western pharmaceutical companies continue to lead in global commercialisation, regulatory expertise, late-stage clinical development, and international market access.


The result is a powerful new model for growth: cross-border collaboration.

From co-development partnerships and globally integrated clinical trials to manufacturing expansion and technology transfer, East–West collaboration is increasingly shaping the future of biopharma innovation.


For companies willing to embrace this shift, the opportunities are significant.


A New Global Model for Biopharma Innovation


One of the clearest signs of this transformation is the dramatic increase in licensing and partnership activity between Western pharmaceutical companies and Eastern biotech innovators.


According to Jefferies, approximately one-third of global drug licensing spending in 2025 involved assets sourced from China — a remarkable shift that would have been difficult to imagine just a decade ago. Western pharmaceutical companies are increasingly licensing innovative Chinese-originated biologics, including bispecific antibodies, antibody-drug conjugates (ADCs), and metabolic therapies such as GLP-1 candidates.


This trend reflects a broader reality: innovation is becoming globally distributed.

China’s biotech sector has rapidly evolved from a generics-focused industry into a growing source of first- and best-in-class therapeutics. South Korea has established itself as a global leader in biologics manufacturing and cell therapy innovation. Singapore continues to strengthen its position as a translational research and biotech investment hub.


At the same time, Western companies remain essential partners in:

  • global commercialisation,

  • late-stage development,

  • regulatory navigation,

  • and international market access.


Increasingly, the future of biopharma is being built through complementary strengths rather than regional competition.


References



The Rise of East–West Co-Development


Perhaps the strongest evidence of this shift can be seen in the growing number of strategic co-development partnerships between Western pharmaceutical companies and Eastern biotech firms.


These collaborations are no longer limited to licensing transactions. They increasingly involve shared R&D efforts, joint clinical development strategies, and long-term innovation partnerships.


Recent examples include:

  • AstraZeneca’s collaboration with CSPC Pharmaceutical Group focused on obesity and type 2 diabetes therapies,

  • Bristol Myers Squibb’s strategic agreements with Hengrui Pharma across oncology, hematology, and immunology,

  • and Pfizer’s collaboration with Fosun Pharma subsidiary Yao Pharma.


These partnerships demonstrate how Eastern biotech companies are becoming important sources of highly competitive scientific innovation, while Western companies provide global development and commercialisation capabilities.


Importantly, the relationship is evolving beyond traditional outsourcing models. The industry is moving toward true co-innovation.


For biotech executives, this shift has strategic implications. Companies that can effectively navigate international collaboration ecosystems may gain access to:

  • broader innovation pipelines,

  • faster development opportunities,

  • diversified manufacturing capabilities,

  • and expanded global market reach.


References


Clinical Research Is Becoming Truly Global


Clinical development is also becoming increasingly international.


As biotech companies seek to accelerate development timelines and improve trial efficiency, Asia-Pacific markets are playing a growing role in global clinical research strategies. Companies are increasingly leveraging the region for:

  • faster patient recruitment,

  • larger patient populations,

  • cost efficiency,

  • and expanding regulatory sophistication.


China has emerged as a major destination for clinical trials. The country’s growing scientific infrastructure and improving regulatory environment have made it increasingly attractive for global development programs.


More broadly, the globalisation of clinical research reflects an important industry reality: innovation can no longer be developed effectively within isolated regional ecosystems.


An important driver behind China’s growing influence in global clinical research has been the rise of Investigator Initiated Trials (IITs).


Unlike traditional sponsor-led studies, IITs are typically designed and initiated by physicians or academic investigators, allowing earlier scientific exploration, faster hypothesis testing, and more flexible clinical experimentation. China’s evolving regulatory environment has increasingly enabled hospitals, researchers, and biotech companies to leverage IITs to accelerate translational research and early clinical validation.


This flexibility has contributed significantly to the rapid advancement of innovative modalities such as:

  • CAR-T therapies,

  • bispecific antibodies,

  • antibody-drug conjugates (ADCs),

  • and next-generation immunotherapies.


For emerging biotech companies, IIT pathways can offer important advantages:

  • faster study initiation,

  • lower development costs,

  • earlier proof-of-concept generation,

  • and stronger collaboration between academia, hospitals, and industry.


As a result, China’s clinical ecosystem has become increasingly attractive not only for domestic innovators but also for global pharmaceutical companies seeking faster and more adaptive development pathways.


The rise of IIT-driven innovation also reflects a broader trend across Asia-Pacific: regulatory systems are evolving to support more agile and collaborative clinical development models. This is helping accelerate the region’s transition from a supporting role in global trials to a central position in next-generation therapeutic innovation.


The future of drug development will depend on globally integrated clinical networks capable of combining scientific expertise, operational efficiency, and patient access across multiple regions.


References





Manufacturing Collaboration Is Becoming a Strategic Growth Driver


Another major area of East–West collaboration is advanced biopharmaceutical manufacturing.


Historically, manufacturing partnerships in Asia were often viewed primarily through a cost-reduction lens. Today, however, the conversation is shifting toward scalability, operational excellence, technological sophistication, and manufacturing resilience.


Eastern manufacturing ecosystems are becoming increasingly important strategic partners for global biotech companies seeking to:

  • scale production capacity,

  • access reliable bioprocessing infrastructure,

  • improve flexibility,

  • and accelerate technology deployment.


Western pharmaceutical companies are responding with long-term investments into Eastern manufacturing capabilities. AstraZeneca’s expansion of its Shanghai production facility to support its cell therapy strategy is one example of how manufacturing collaboration is becoming deeply integrated into broader innovation strategies.


Companies like Sartorius are playing an increasingly important role in enabling the global scale-up of biologics manufacturing by providing advanced bioprocessing technologies, high-productivity CHO (Chinese Hamster Ovary) cell lines, filtration systems, single-use bioreactors, and digital manufacturing solutions. Sartorius’s recently introduced genetically engineered CHO host cell line is designed to improve biologics yield and production efficiency, helping manufacturers accelerate process development while reducing operational complexity and costs. Beyond equipment supply, companies like Sartorius are helping strengthen the broader manufacturing ecosystem required to support the growing global demand for monoclonal antibodies, cell therapies, and next-generation biologics.


At the same time, technology providers across Asia-Pacific are helping advance manufacturing productivity and process optimisation. Innovations in cell line engineering, bioprocess equipment, and manufacturing systems are further strengthening the region’s role in next-generation biologics production.

The industry is no longer thinking purely in terms of “manufacturing outsourcing.” Instead, manufacturing is becoming a strategic partnership area that directly influences innovation speed and global competitiveness.


References





Advanced Therapies Are Creating New Regional Innovation Bridges


One of the most exciting dimensions of East–West collaboration is emerging in advanced therapies, including cell and gene therapies.


These highly specialised technologies require extensive scientific expertise, manufacturing coordination, and international collaboration. As a result, they are accelerating the creation of new regional innovation bridges.


A compelling example is the collaboration involving Türkiye’s TÜSEB and TCT Health Technologies together with South Korea’s AbClon in the field of CAR-T cell therapy development.


This type of partnership demonstrates how emerging biotechnology ecosystems can work together to accelerate capability development, technology transfer, and access to advanced therapies.


It also highlights Türkiye’s growing potential as a strategic regional life sciences hub.

Positioned between Europe, Asia, and the Middle East, Türkiye offers important advantages for:

  • regional manufacturing,

  • clinical research,

  • supply chain coordination,

  • and cross-border healthcare collaboration.


From Sweden, NextCell Pharma provides a strong example through its strategic expansion into Hong Kong to strengthen partnerships, access Asian investors, and engage with the region’s growing cell therapy ecosystem. The company’s move reflects how emerging European biotech firms are increasingly viewing Asia not only as a commercial market, but also as a long-term innovation and collaboration partner.


Another example of growing East–West collaboration can be seen in Epigenica’s expansion into Japan through a partnership with PrimeTech to advance epigenetic research and precision medicine capabilities. The collaboration demonstrates how specialised European biotech SMEs are increasingly leveraging partnerships across Asia to accelerate scientific adoption, strengthen regional research networks, and expand access to advanced technologies. It also reflects the growing importance of Japan as a strategic innovation partner within the broader Asia-Pacific life sciences ecosystem, particularly in areas such as genomics, biomarker discovery, and translational medicine.


As advanced therapies continue to evolve globally, partnerships that connect scientific expertise across regions may become increasingly important for expanding access and accelerating innovation.


References





Advanced Therapies and Emerging Innovation Ecosystems Are Creating New East–West Bridges: United Kingdom, Sweden and Türkiye


One of the most exciting dimensions of East–West collaboration is emerging in advanced therapies, precision medicine, and next-generation biotechnology platforms. Increasingly, innovation is no longer flowing through a small number of traditional biotech hubs alone. Instead, regional ecosystems across Türkiye, Sweden, the UK, and Asia-Pacific are building new cross-border partnerships that combine scientific expertise, manufacturing capabilities, and translational research strengths.

A strong example is the collaboration involving Türkiye’s TÜSEB and TCT Health Technologies together with South Korea’s AbClon in the field of CAR-T cell therapy development. The partnership demonstrates how international cooperation can accelerate technology transfer, advanced therapy manufacturing capabilities, and regional innovation development.

Sweden is also becoming increasingly active in East–West life sciences collaboration. Swedish biotech company Epigenica recently expanded into Japan through a partnership with PrimeTech to support epigenetic research and precision medicine initiatives. The collaboration highlights how specialized European biotech SMEs are increasingly leveraging partnerships across Asia to strengthen research networks and accelerate scientific adoption in emerging healthcare markets.

Similarly, UK-based life sciences and healthtech ecosystems are deepening engagement with Asia-Pacific through partnerships focused on innovation exchange, regulatory collaboration, and international commercialization opportunities. These initiatives reflect a broader industry shift toward globally connected innovation ecosystems where scientific progress, manufacturing, and market expansion are increasingly built through international collaboration.

Together, these examples demonstrate how the future of life sciences innovation may increasingly depend on the ability to connect complementary capabilities across regions — combining Western scientific and commercial expertise with the rapidly advancing innovation and manufacturing ecosystems emerging across Asia-Pacific.



How Sarem Consulting Supports Cross-Border Collaboration


As the life sciences industry becomes more globally interconnected, organisations increasingly need experienced partners capable of bridging regional ecosystems.


Sarem Consulting supports companies in Türkiye, Sweden, the UK and others by helping facilitate strategic collaboration opportunities between Eastern and Western life sciences stakeholders.


This includes supporting organisations in areas such as:

  • sourcing reliable and scalable bioprocess and manufacturing technologies from Asia,

  • connecting with trusted suppliers and technology partners,

  • supporting manufacturing capability expansion,

  • facilitating cross-border partnership discussions,

  • and helping organisations navigate the complexities of international collaboration.


As innovation ecosystems continue to globalise, effective coordination between scientific, operational, and commercial stakeholders will become increasingly important.

Companies that can successfully build trusted international partnerships may be better positioned to accelerate innovation, scale manufacturing capabilities, and expand access to next-generation therapies.



The Future Will Belong to Collaborative Ecosystems


The next era of biopharma innovation will likely be defined less by geography and more by connectivity.


No single region holds all the capabilities required to drive the future of healthcare innovation alone. Scientific discovery, clinical development, advanced manufacturing, and commercialisation are becoming increasingly distributed across global ecosystems.


The organisations that succeed in this environment will be those capable of:

  • building trusted international partnerships,

  • integrating complementary capabilities across regions,

  • and transforming collaboration into scalable healthcare impact.


East–West collaboration is no longer simply an operational strategy.


It is becoming a foundational pillar of the future life sciences industry.


And for organisations willing to embrace this shift, the opportunities ahead may be transformative.

Comments

bottom of page